Ligand Pharmaceuticals LGND Tax receivable within other current assets
Tax receivable within other current assets at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxesReceivable.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's tax receivable within other current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's tax receivable within other current assets?
- Ligand Pharmaceuticals (LGND) reported tax receivable within other current assets of $1.42M in Q1 2026.
- How has Ligand Pharmaceuticals's tax receivable within other current assets changed year-over-year?
- Ligand Pharmaceuticals's tax receivable within other current assets decreased by 67.4% year-over-year, from $4.34M to $1.42M.
- What is the long-term trend for Ligand Pharmaceuticals's tax receivable within other current assets?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's tax receivable within other current assets has grown at a -8.2% compound annual growth rate (CAGR), from $2.22M to $1.45M.